相关临床试验
1
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1960
招募中
1
100.0%
暂无批准数据
- Researchers from Monash University and the Hudson Institute of Medical Research have created the first organoid models combining a patient's intestinal lining with their own gut bacteria to study inflammation. - The 'mini guts' allow scientists to test how individual patients' bacteria drive inflammation, moving beyond a 'one-size-fits-all' approach toward personalised IBD treatment. - The team has built a living biobank of matched organoids and bacterial collections from paediatric Australian patients, laying groundwork for testing tailored interventions before they reach the bedside. - IBD affects an estimated 180,000 Australians, with prevalence projected to reach 1 per cent of the population by about 2030, underscoring the urgent need for more precise therapies.
- Australian biotech Cleo Diagnostics received constructive FDA feedback during its second pre-submission meeting, reinforcing confidence in its 510(k) regulatory strategy for an ovarian cancer triage test. - The company's blood-based diagnostic utilizes the patented CXCL10 biomarker, which is produced at high levels by ovarian cancers but largely absent in non-malignant disease. - FDA guidance addressed critical technical elements including clinical trial design and sample stability, positioning Cleo to proceed with greater confidence toward its 2024 submission. - The test has been validated in clinical studies involving over 500 patients and aims to support more accurate pre-surgical triage for ovarian cancer, one of the deadliest gynecological malignancies.
- Researchers at Hudson Institute of Medical Research discovered that Pirfenidone, a drug used to treat lung fibrosis, effectively reduces both viral replication and airway inflammation in COPD without suppressing immune response. - The pre-clinical study found Pirfenidone outperformed steroids in managing COPD exacerbations while avoiding the severe side effects associated with long-term steroid use, including diabetes, hypertension, and osteoporosis. - COPD affects approximately 2 million Australians and current steroid treatments create a paradox by reducing inflammation but encouraging viral replication during exacerbations. - The findings, published in the American Journal of Respiratory Cell and Molecular Biology, suggest Pirfenidone could allow patients to discontinue steroids and prevent severe COPD flares that can lead to premature death.
- Hudson Institute researchers advance groundbreaking extracellular vesicle treatment derived from amniotic cells into clinical trials for complex perianal Crohn's disease, offering a potential cost-effective alternative to stem cell therapy. - The first-in-human trial will evaluate the safety and efficacy of hAEC-EV therapy in 15 participants with refractory Crohn's perianal fistulas, marking the second human EV trial in Australia. - With the global Crohn's disease market projected to reach $13.4 billion by 2026, this innovative approach could provide a more accessible treatment option for the one-third of patients who develop fistulas.
